Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s ...

Core Insights - Clearmind Medicine Inc. has filed a patent application for a novel combination therapy aimed at treating major depressive disorder (MDD), which is projected to be a significant market exceeding $25 billion by 2030 [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics to address major health issues, including MDD and alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, with 31 granted patents, and plans to pursue additional patents to enhance its intellectual property [5] Treatment Innovation - The new treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), developed in partnership with NeuroThera Labs Inc. [2] - This MEAI-PEA synergy is positioned as a safer and more accessible alternative to traditional antidepressants, potentially benefiting over 332 million people globally suffering from depression [3]